Sparekassen Kronjylland, number one in customer satisfaction, signs Agillic to raise the bar
Sparekassen Kronjylland, among Denmark's ten largest financial institutions, is organised around making a positive difference for the customers with a defined purpose to build life-long relationships and help customers get the best of their finance. As a guarantee savings bank, they aim to leverage the flexibility of not having shareholders to also make a difference in the local communities by supporting associations, clubs, and cultural institutions.
Customer satisfaction is the most important metric to Sparekassen Kronjylland and whilst ranking number one within banking in Denmark, they push to constantly improve and deliver ever more relevant information and customer experiences.
Trine Kastrup Berthelsen, Project Manager at Sparekassen Kronjylland explains: 'Our promise to customers is financial security and our advisors work hard to foster trusted relationships by providing the most relevant guidance and advice at any given time. With Agillic, we have a modern platform to complement their effort and one that not only provides immediate impact but also scales long term as we continue to evolve our ambitions for how individualised our information and communication can and should be.'
Bo Sannung, Chief Solution Officer at Agillic adds: 'Agillic's ability to deliver highly individual customer experiences and personalised communication, and with uncompromising compliance on privacy and security, is critical for financial businesses. Welcoming Sparekassen Kronjylland, already number one in customer satisfaction, is a testament to that and we are proud to help them deliver as they continue to raise the bar on customer relationships.'
For further information, please contactChristian Samsøe, CEO+45 24 88 24 24christian.samsoe@agillic.com
About Agillic A/SAgillic A/S (Nasdaq First North Growth Market Copenhagen: AGILC) is a Danish software company offering brands a platform through which they can work with data-driven insights and content to create, automate, and send personalised communication to millions. Agillic is headquartered in Copenhagen, Denmark. For further information, please visit agillic.com.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
1 Reason to Buy NVO
Key Points It is clearly very effective at developing drugs. Its Wegovy recently earned FDA approval for a new indication. 10 stocks we like better than Novo Nordisk › It's one thing for a pharmaceutical company to have a blockbuster drug in its portfolio. It's quite another if such a product can be successfully extended to win approvals for other indications. This is one huge reason to believe in the future of Novo Nordisk (NYSE: NVO), the Danish company behind the immensely popular Wegovy obesity treatment. Last week the company earned a new feather in its cap with the product, and it feels as if it has far more distance to go with drug discovery. Wegovy has legs In mid-August the company hit paydirt when the U.S. Food and Drug Administration (FDA) approved it as a treatment for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adult patients with moderate to advanced liver fibrosis. The drug is intended to be used in combination with an increase in physical activity, and a reduction in caloric food intake. It probably goes without saying that America's obesity problem affects far more individuals than does MASH. But Novo Nordisk's successful development of the drug to treat the liver disorder demonstrates two very positive things; 1) Wegovy (and by extension its sibling medication, Ozempic) has the potential to treat numerous other afflictions and, 2) generally, the company is adept at developing its molecules for a variety of indications. Pipeline to greater success? Novo Nordisk has quite the impressively wide pipeline, and semaglutide (the molecule which is the primary ingredient of Wegovy and Ozempic) is only one part of it. It's in the later stages of investigating the drug for treatment of Alzheimer's; meanwhile, it's got a host of other molecules in programs aimed in many therapeutic directions. With such a high pitch of activity, the future is bright for semaglutide and other investigational drugs. And, by extension, their developer. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Reason to Buy NVO was originally published by The Motley Fool
Yahoo
16 hours ago
- Yahoo
GoodRx Is Soaring on a Novo Nordisk Deal. Should You Buy GDRX Stock Here?
GoodRx (GDRX) shares soared nearly 50% on Monday after announcing a GLP-1 partnership with the Danish pharmaceutical behemoth Novo Nordisk (NVO). In a press release this morning, the Nasdaq-listed firm said 'all strengths of Ozempic and Wegovy pens are now available to eligible self-paying patients for $499-per-month through GoodRx.' More News from Barchart Trade the Warren Buffett Rally in UnitedHealth Stock With This High-Reward, Low-Risk Options Strategy Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Cathie Wood Is Buying BLSH Stock After the Bullish IPO. Should You? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! GoodRx stock has slightly outperformed in 2025, up just over 12% in the year to date. How Novo Deal May Help GoodRx Stock Teaming up with Novo Nordisk is a major win for GDRX shares because it positions the healthcare platform at the center of the booming GLP-1 weight-loss and diabetes drug market. Offering Ozempic and Wegovy at a flat $499 per month to self-paying customers helps GoodRx expand access to high-demand medications while reinforcing its value proposition as a cost-saving platform. Over time, this could drive user growth, boost engagement, and attract new pharmacy and pharma partnerships as well. In short, with GLP-1 drugs making headlines and consumer interest soaring, GoodRx stock is now tied to one of the most lucrative trends in healthcare. Why BofA Remains Bearish on GDRX Shares Despite the aforementioned positives, Bank of America analyst Allen Lutz says the Novo Nordisk deal is far from a sufficient reason to load up on GoodRx shares at current levels. In a note to clients, Lutz argued widespread pharmacy closures and changing reimbursement policy could make it difficult for GDRX stock to retain momentum in the days ahead. On Monday, the BofA analyst maintained his 'Underperform' rating and $3.40 price target on the healthcare platform, indicating potential downside of more than 30% from here. Wall Street Disagrees with BofA on GoodRx Investors should note, however, that Bank of America Securities is among the more bearish Wall Street firms on GoodRx stock in 2025. According to Barchart, the consensus rating on GDRX shares remains at 'Moderate Buy' with the mean target of $5.49 indicating potential 'upside' of another 5% from current levels. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
a day ago
- Business Insider
The tech industry seems to be spiraling, and I want to leave. My career has been dipping, and layoffs are impossible to avoid.
This as-told-to essay is based on a transcribed conversation with 28-year-old Melody Koh, a product designer from Germany. The following has been edited for length and clarity. I've worked in tech for just under 10 years. The first half of my career and the second half tell completely different stories. I built a career as a product designer working for startups, but my career has dipped since 2021. After being laid off in May 2025, I was unemployed for over two months. In August, I landed an opportunity to work as a contractor on product design for an e-commerce company. It's tech-adjacent, but since the focus is more on retail, I'm hoping it can help me eventually pivot away from the tech industry. I don't want to work in tech anymore. The industry has been moving in a downward spiral, with and companies being less generous. I don't think that the tech job market is going to get better. I built a career in tech, focused on design I studied experience and product design at a polytechnic in Singapore. I was learning to design spaces and furniture, but I grew interested in digital design, such as user experience (UX) design. My tech career began with freelance work for a few start-ups during my studies. I built up my portfolio designing for apps and websites, and went on to work at tech startups after finishing my diploma in 2017. Digitalization was a big deal at the time. I felt there would be a lot of demand for my skills and a good industry to build my career. Between 2018 and 2022, I worked for a few startups focused on crypto and blockchains, where I learned a lot about the technology behind those kinds of products. There were always interesting design problems to solve. In 2021, I relocated to Europe, where I live now, for a fintech role. In 2022, I lost my job due to an insolvency. After that, I worked for a data company, a Danish fintech unicorn, and then pivoted to an EdTech company, but I was laid off from the EdTech in May 2025. The tech industry is in a downward spiral When I first started working in tech, there was a lot of innovation and discovery around products, and I was building a lot of new things. Nowadays, many product playbooks are already made. There are also more resources designers can implement into their own work, but it feels like you're mimicking something that already exists. Being a designer gets diluted when you're not creating anything new. In my experience, founders were more generous with their funding than they are now. Hard work used to be well-rewarded, but now, I don't think startup employees see good rewards. Earlier in my career, we'd always celebrate something good happening by going for team lunches or team trips. This has been less common for me recently. It wasn't like we got everything we wanted, but there was a work-hard, play-hard environment. When I moved from the unicorn I was working at to my last job at an EdTech company, I took a pay cut — partly because I wanted to make an impact in the education space. Efficiency pushes are hurting employees I don't think changes have happened because there's less money in the industry. I think it's because companies are trying to become more efficient. They're cutting fat, and employees are getting the short end of the stick. My friends at corporate companies get job stability, a clear career progression, and corporate discounts. They may make less money than I do, but they can use their job stability to build wealth. Meanwhile, I've been in and out of employment during my career. Since finishing my diploma in 2017, I've worked for six tech startups. Years ago, if you weren't happy with your pay, you could leave and find another job. It was never easy to find a job in tech — you need technical knowledge — but nowadays, it feels like the amount of talent saturation makes it harder to land roles. It's switched from an employee's market to an employer's market. Companies overhired during COVID. I lost my job to insolvency in 2022. The industry was never the most stable, but since 2022, I feel like layoffs have become so common that it's almost impossible not to get laid off. I'm seriously considering leaving tech I don't regret my career in tech. I've been challenged, and I've grown a lot as a designer. After being laid off in May, I was job-searching for three months. I applied to around 60 jobs, but received a lot of rejections before landing my current role. I've been working on multiple side projects, including writing on Medium and starting a product studio. I plan to continue working on these in conjunction with my new job. I'm considering what I should do next. I would probably like to focus on designing physical products instead of digital ones. It will be difficult to convince me to work for tech companies. I don't think it's worth it.
